Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
liposomal irinotecan + cisplatin
- Development stage
- Unknown
- Lead developer
- Ipsen
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
Liposomal irinotecan + cisplatin is an investigational combination chemotherapy regimen consisting of a nanoliposomal formulation of irinotecan (a topoisomerase I inhibitor) and cisplatin (a platinum-based DNA crosslinking agent). The regimen is being evaluated in the Phase I ICONIC study, sponsored by the National Health Research Institutes (NHRI) in Taiwan, for the treatment of advanced or metastatic solid malignancies. The liposomal delivery system for irinotecan is designed to improve the drug's pharmacokinetic profile and tumor penetration by protecting the active lactone form of the drug and extending its half-life in circulation. Cisplatin works synergistically by forming inter- and intra-strand DNA crosslinks, which induce DNA damage and subsequent apoptosis in cancer cells.
- Brand names
- ONIVYDE + cisplatin
- Other names
- nanoliposomal irinotecan + cisplatinliposomal irinotecan and cisplatin
02
Targets
TOP1 (DNA Topoisomerase I)DNA
Beyond the preview
Go deeper on liposomal irinotecan + cisplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on liposomal irinotecan + cisplatin.